BPC-157
Stable pentadecapeptide derived from human gastric juice; appears to drive angiogenesis-mediated tissue repair via VEGF, eNOS, and growth-hormone receptor pathways.
BPC-157 (Body Protection Compound) is a synthetic 15-residue peptide originally identified as a stable fragment of a larger protein found in human gastric juice. Unlike most peptides of comparable length, BPC-157 demonstrates remarkable stability across pH ranges and resistance to proteolytic digestion, making it one of the few peptide molecules under investigation for oral bioavailability.
The compound’s research profile centers on accelerated tissue regeneration. Across rodent models of tendon, ligament, muscle, bone, and gastrointestinal injury, BPC-157 administration is associated with up-regulation of vascular endothelial growth factor (VEGF), enhanced expression of endothelial nitric oxide synthase (eNOS), and modulation of the nitric oxide system. These effects appear to drive the consistent acceleration of capillary network formation observed in healing tissue. A secondary mechanism involves up-regulation of the growth-hormone receptor in fibroblasts and tenocytes, potentially explaining BPC-157’s outsized impact on collagen-rich tissues.
Clinical translation remains limited. To date, the strongest evidence comes from preclinical Sprague-Dawley rat models; controlled human trials are sparse. Routes of administration studied include intraperitoneal, subcutaneous, intramuscular, and (with the stable acetate form) oral. BPC-157 remains classified for research use only; no regulatory body has approved it for any therapeutic indication.